49
edits
Changes
→References
==References==
==References==
1. Alvarez Argote J, Dasanu CA, (2018). ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival. Curr Med Red Opin 34(5):757-763. PMID 28027687
2. Jacobs JJ, van Lohuizen M, (2002). Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 1602(2):151-61. PMID 12020801
3. Xiong B, et al., (2014). Characterization of side population cells isolated from the colon cancer cell line SW480. Int J Oncol 45(30:1175-1183. PMID 24926880
4. Fisher CL, et al., (2006). Characterization of Asxl1, a murine homolog of Additional sex combs, and analysis of the Asx-like gene family. Gene 369:109-118. PMID 16412590
5. Gelsi-Boyer V, et al., (2009). Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145:788-800. PMID 19388938
6. Carbuccia N, et al., (2009). Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 23(11);2183-2186. PMID 19609284
7. Abdel-Wahab O, et al., (2012). ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22(20):180-193. PMID 22897849
8. Lindsley RC, et al., (2015). Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125(9):1367-1376. PMID 25550361
9. Schnittger S, et al., (2013). ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 27(1):82-91. PMID 23018865
10. Shen H, et al., (2015). CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia. Leuk Lymphoma 56(3):820-822. PMID 25005031
11. Pellagatti A, et al., (2016). Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression. Leukemia 30(10:247-250. PMID 25991409
12. Chou WC, et al., (2010). Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like (ASXL1) mutations. Blood 116(20):4086-4094. PMID 20693432
13. Devillier R, et al., (2015). Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasic-related changes. Oncotarget 2015;6(10:8388-8396. PMID 25860933
14. Patnaik MM, et al., (2014). ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia 28(11):2206-2212. PMID 24695057
15. Patnaik MM, et al., (2013). Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 27(7):1504-1510. PMID 23531518
16. Chen TC, et al., (2014). Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome. Blood Cancer J 4:e177. PMID 24442206
17. Thol F, et al., (2011). Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 29(18):2499-2506. PMID 21576631
18. Papaemmanuil E, et al., (2016). Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374(23):2209-2221. PMID 27276561
19. Itzykson R, et al., (2013). Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 31(19):2428-2436. PMID 23690417
20. Metzeler KH, et al., (2011). ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 118(26):6920-6929. PMID 22031865
21. Tefferi A, et al., (2014). Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89(9):915-925. PMID 25124313
22. Williams DS, et al., (2010). Nonsense mediated decay resistant mutations are a source of expressed mutant proteins in colon cancer cell lines with microsatellite instability. PLoS One 5(12):e16012. PMID 21209843
== Notes ==
== Notes ==